Guardant Health, Inc. (NASDAQ:GH) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Guardant Health, Inc. has received a consensus rating of "Moderate Buy" from analysts, with 23 out of 24 analysts issuing buy ratings on the stock.
• The average 12-month price target set by brokers for Guardant Health is $65.86, reflecting a positive outlook from the investment community.
• Recent insider trading included significant sales by both the director and CEO, indicating a 71.78% and 12.38% decrease in their holdings, respectively.

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-four ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and twenty-three have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $65.8571.

A number of equities analysts have recently commented on the stock. William Blair reissued an "outperform" rating on shares of Guardant Health in a research note on Thursday, September 25th. Wolfe Research raised shares of Guardant Health from a "peer perform" rating to an "outperform" rating and set a $75.00 target price on the stock in a research note on Thursday, September 25th. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $60.00 to $70.00 and gave the stock an "overweight" rating in a research note on Thursday, September 25th. Wells Fargo & Company started coverage on shares of Guardant Health in a research note on Monday, September 22nd. They set an "overweight" rating and a $72.00 price target on the stock. Finally, Guggenheim lifted their price target on shares of Guardant Health from $56.00 to $67.00 and gave the stock a "buy" rating in a research note on Thursday, September 25th.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, Director Medina Manuel Hidalgo sold 2,165 shares of the firm's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $54.16, for a total transaction of $117,256.40. Following the completion of the transaction, the director directly owned 851 shares of the company's stock, valued at $46,090.16. This trade represents a 71.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Helmy Eltoukhy sold 300,000 shares of the firm's stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the transaction, the chief executive officer directly owned 2,123,499 shares of the company's stock, valued at approximately $126,242,015.55. This represents a 12.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 302,691 shares of company stock worth $17,981,965 in the last ninety days. 6.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Guardant Health

Institutional investors have recently modified their holdings of the business. Signaturefd LLC raised its stake in Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company's stock worth $33,000 after acquiring an additional 213 shares during the period. IFP Advisors Inc boosted its stake in Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company's stock valued at $33,000 after acquiring an additional 334 shares during the period. Allworth Financial LP boosted its stake in Guardant Health by 358.4% in the second quarter. Allworth Financial LP now owns 706 shares of the company's stock valued at $37,000 after acquiring an additional 552 shares during the period. Sound Income Strategies LLC acquired a new position in Guardant Health in the third quarter valued at approximately $38,000. Finally, SVB Wealth LLC acquired a new position in Guardant Health in the first quarter valued at approximately $54,000. Institutional investors own 92.60% of the company's stock.

Guardant Health Stock Performance

Shares of GH stock opened at $64.22 on Friday. Guardant Health has a one year low of $20.14 and a one year high of $68.00. The company has a 50 day moving average price of $59.43 and a 200 day moving average price of $50.17. The firm has a market capitalization of $8.01 billion, a price-to-earnings ratio of -19.17 and a beta of 1.53.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.08. The business had revenue of $232.09 million during the quarter, compared to analysts' expectations of $211.19 million. During the same period in the prior year, the business posted ($0.84) EPS. The business's revenue was up 31.0% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Guardant Health will post -2.9 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.